Why URAH works when the pills didn't
From application to circulation
The oral route
Swallowed glucosamine passes through digestion and first-pass liver metabolism before reaching circulation. An ordinary cream faces the opposite problem: glucosamine does not cross the skin barrier on its own.
The URAH route
URAH wraps each glucosamine molecule in a microscopic micellar carrier designed to cross the skin barrier intact.
Applied over the joint you want to support.
Micellar carriers take glucosamine across the skin barrier.
Concentration begins at the applied area.
Glucosamine enters the bloodstream.
Circulation carries it further.
Starts at the site of application. Circulation carries it further.
Ten times more glucosamine absorbed
Transdermal delivery bypasses digestion and liver metabolism. This study measured what difference that makes.
more glucosamine absorbed into the bloodstream
If oral glucosamine never worked for you, the issue may not be the ingredient. It may be the route.
The gap in the knee got wider, not narrower
All groups used the same cream — URAH. Only the method of application differed. One group applied it by hand, as a patient would at home.
What they measured
Medial joint space width is the distance between the bones on imaging — the standard structural marker in knee osteoarthritis research, used as an indirect indicator of cartilage thickness.*A narrower space suggests more degeneration. A wider one points the other way.
What they found
In the hand-applied group, mean medial joint space width increased over 12 weeks.
increase in medial joint space width
The study also reported significant decreases in degenerative changes at the knee joint after 12 weeks.2
Knee osteoarthritis normally moves the other way.Joint space narrows as degeneration progresses. This was a measured change in the opposite direction.
Pain scores improved in four weeks
Patients used URAH in ordinary outpatient clinics for four weeks. Their doctors recorded pain, function, compliance and safety.
RAI pain scores improved from baseline across all demographic groups3
Good opinion among shoulder, neck and back arthritis patients
Good opinion for ankle, wrist and elbow osteoarthritis
Completed the minimum four-week routine (42 of 44 patients)
Reported adverse reactions or skin irritation
The paper concluded that URAH transdermal glucosamine cream alleviated pain in arthritic joints over four weeks of use, and linked the safety and compliance findings to the practical advantages of the transdermal route — particularly the avoidance of gastrointestinal side effects associated with oral formulations.3
Pain scores improved within four weeks, with high routine completion and no reported adverse reactions.
Every batch is tested.
1. Active-ingredient verification
2. Emulsion stability
3. Skin-safe pH
4. Microbial screening
5. Heavy-metal analysis
It isn't one study. It's a pattern.
Micellar transdermal delivery, patented in the US, Japan and Singapore
Up to 10× more glucosamine measured in the bloodstream than the oral form
61% increase in measured medial joint space width over 12 weeks
Pain scores improved over four weeks across 16 clinics
No adverse reactions reported in the clinical survey; over 15 years of real-world use
Every batch tested for strength, stability, pH, microbes and heavy metals
Common questions
Joint space width is an indirect measure of cartilage thickness — the standard structural marker in knee osteoarthritis research. This study recorded a measurable change over 12 weeks, in the opposite direction to the usual course of the disease. Further research is planned.
Concentration begins at the site of application, and absorbed glucosamine then circulates further. The omega-3 component acts locally where applied.
No. Glucosamine does not cross the skin barrier on its own — a cream can contain it and leave most of it on the surface. URAH uses patented micellar transdermal delivery, and is the formulation used in the studies cited here.
Four to twelve weeks of consistent daily use. Pain improvement was measured at four weeks; structural change at twelve.
No. It is daily joint support, not an NSAID or numbing cream.
Sources cited on this page.
- Bioavailability of transdermal micellar glucosamine. BMC Research Notes, 2016. View the paper →
- Symptoms-modifying effects of electromotive administration of glucosamine sulphate among patients with knee osteoarthritis. Hong Kong Physiotherapy Journal, 2018. Glucosamine sulphate 8% w/w cream (URAH), 12 weeks. View the paper →
- Transdermal glucosamine cream in mild-to-moderate osteoarthritis: outpatient clinical survey. 16 clinics, Singapore; 44 patients; 4 weeks. View the survey →
The formulation used in these studies
URAH Joint Health Omega-3
The formulation studied in the knee osteoarthritis and clinical-survey research on this page. For everyday joint stiffness, knee osteoarthritis, mobility and age-related joint wear.
